Iproclozide

Iproclozide.svg

Antidepressant drug

Engineered Monoclonal Antibodies

Diagram of engineered monoclonal antibodies

Engineered monoclonal antibodies are a class of biological therapies that are designed to target specific antigens on the surface of cells. These antibodies are produced using recombinant DNA technologies and are used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

Structure and Function

Monoclonal antibodies are composed of two identical heavy chains and two identical light chains, forming a Y-shaped molecule. The tips of the "Y" contain the antigen-binding sites, which are highly specific to the target antigen. This specificity allows monoclonal antibodies to bind to their target with high affinity, blocking or modulating the function of the antigen.

Types of Engineered Monoclonal Antibodies

There are several types of engineered monoclonal antibodies, each designed for specific therapeutic purposes:

• Chimeric antibodies: These antibodies are composed of murine (mouse) variable regions and human constant regions. They are less immunogenic than fully murine antibodies.

• Humanized antibodies: These antibodies are mostly human, with only the antigen-binding sites derived from murine sources. This reduces the risk of immune reactions.

• Fully human antibodies: These are entirely human in origin, produced using transgenic mice or phage display technologies.

• Bispecific antibodies: These antibodies are engineered to bind two different antigens simultaneously, offering unique therapeutic mechanisms.

Applications in Medicine

Engineered monoclonal antibodies have revolutionized the treatment of many diseases:

• Cancer therapy: Monoclonal antibodies can target specific tumor antigens, leading to direct tumor cell killing or recruitment of immune cells to attack the tumor.

• Autoimmune diseases: By targeting specific components of the immune system, monoclonal antibodies can reduce inflammation and tissue damage in diseases such as rheumatoid arthritis and multiple sclerosis.

• Infectious diseases: Monoclonal antibodies can neutralize pathogens or their toxins, providing passive immunity or enhancing the host's immune response.

Production

The production of engineered monoclonal antibodies involves several steps:

1. Antigen identification: The target antigen is identified and characterized. 2. Hybridoma technology: B cells from immunized animals are fused with myeloma cells to create hybridomas that produce the desired antibody. 3. Recombinant DNA technology: Genes encoding the antibody are cloned and expressed in suitable host cells, such as Chinese hamster ovary cells. 4. Purification and formulation: The antibodies are purified and formulated for clinical use.

Challenges and Future Directions

While engineered monoclonal antibodies have shown great promise, there are challenges such as high production costs, potential for immune reactions, and the development of resistance. Ongoing research aims to improve antibody design, reduce immunogenicity, and enhance therapeutic efficacy.

Related Pages

• Monoclonal antibody therapy
• Biopharmaceutical
• Immunotherapy
• Hybridoma technology

Iproclozide is a monoamine oxidase inhibitor (MAOI) that was used as an antidepressant in the treatment of depression. It belongs to the class of hydrazine derivatives.

Mechanism of Action

Iproclozide works by inhibiting the activity of the enzyme monoamine oxidase (MAO). This enzyme is responsible for breaking down monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine. By inhibiting MAO, iproclozide increases the levels of these neurotransmitters in the brain, which can help alleviate symptoms of depression.

Clinical Use

Iproclozide was primarily used in the treatment of major depressive disorder. However, due to the risk of severe side effects and the development of safer antidepressants, its use has declined.

Side Effects

The use of iproclozide can lead to several side effects, including:

• Hypertensive crisis (especially when taken with tyramine-rich foods)
• Orthostatic hypotension
• Insomnia
• Weight gain
• Sexual dysfunction

Interactions

Iproclozide can interact with various substances, leading to potentially dangerous effects. Notable interactions include:

• Tyramine-rich foods (e.g., aged cheese, cured meats)
• Other antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)
• Sympathomimetic drugs

Withdrawal and Discontinuation

Abrupt discontinuation of iproclozide can lead to withdrawal symptoms, including:

• Anxiety
• Agitation
• Dizziness
• Nausea

History

Iproclozide was developed and introduced in the mid-20th century. It was one of the earlier MAOIs used for the treatment of depression. However, due to its side effect profile and the advent of newer antidepressants, its use has significantly decreased.

See Also

• Monoamine oxidase inhibitor
• Antidepressant
• Major depressive disorder
• Serotonin
• Norepinephrine
• Dopamine

References

This article is a stub related to medicine. You can help WikiMD by expanding it!